Par Pharmaceutical Companies Inc., of Woodcliff Lake, N.J., said it entered a definitive agreement to acquire JHP Group Holdings, the parent company of JHP Pharmaceuticals, a specialty pharmaceutical company that currently markets a portfolio of 14 specialty injectable products, including Aplisol and Adrenalin, and has developed a pipeline of 34 products, 17 of which have been submitted for FDA approval.